Related Experiment Videos
Ovulation induction with pulsatile intravenous GnRH
The Journal of Reproductive Medicine
|December 1, 1985
Summary
Pulsatile gonadotropin-releasing hormone (GnRH) therapy effectively induces ovulation in women with hypogonadotropic hypogonadism resistant to clomiphene citrate. This GnRH treatment resulted in high ovulation and pregnancy rates with no complications and reduced costs.
Area of Science:
- Reproductive Endocrinology
- Infertility Treatment
- Hormone Therapy
Background:
- Human menopausal gonadotropin is a standard treatment for hypogonadotropic hypogonadism unresponsive to clomiphene citrate.
- Gonadotropin-releasing hormone (GnRH) has shown promise for ovulation induction in select patient populations.
Purpose of the Study:
- To evaluate the efficacy and safety of pulsatile intravenous GnRH for ovulation induction in patients with hypogonadotropic hypogonadism.
- To compare the cost-effectiveness of GnRH therapy with human menopausal gonadotropin.
Main Methods:
- Eight patients with hypogonadotropic hypogonadism underwent 15 cycles of pulsatile intravenous GnRH therapy using commercially available GnRH and an infusion pump.
- Ovulation was monitored using basal body temperature charting and ultrasound to assess follicle development.
- Pregnancy outcomes and treatment complications were recorded.
Main Results:
- Ovulation of a single, dominant follicle was documented in 80% of cycles (12 out of 15).
- A corrected pregnancy rate of 40% (four pregnancies in ten cycles) was achieved in six patients (67%).
- Treatment required an average of 12.2 days per cycle, with no observed complications.
Conclusions:
- Pulsatile intravenous GnRH is an effective ovulation induction method for hypogonadotropic hypogonadism patients.
- GnRH therapy offers a cost-effective alternative to human menopausal gonadotropin, with comparable or improved success rates and safety profile.